TransCode Therapeutics and Akribion Genomics Report Proof-Of-Concept Laboratory Studies In Human Cells; Say Studies To Date 'Suggest That Akribion's G-dase E Ribonucleoprotein Complexes Could Be Conjugated to TransCode's TTX Delivery Platform, Suggesting That the Drug Candidate Could Be Formulated as Intended.'
TransCode Therapeutics和Akribion Genomics報告了人體細胞的概念驗證實驗室研究；稱迄今爲止的研究 “表明Akribion的G-dase E核糖核蛋白複合物可以與Transcode的TTX遞送平台偶聯，這表明候選藥物可以按預期配製。”